Molecular diagnosis of tuberculosis and drug resistance

Clinics in Laboratory Medicine

Volumn 34, Issue 2, 2014, Pages 297-314

  Lin, Shou Yean Grace ^a   Desmond, Edward P ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Drug resistance; GeneXpert; Line probes; Molecular detection; Pyrosequencing; Sequencing; Tuberculosis; Tuberculosis diagnostics

Indexed keywords

AMIKACIN; BEDAQUILINE; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASSAY; BACTERIAL MUTATION; DIAGNOSTIC KIT; DNA SEQUENCE; GENE SEQUENCE; GENETIC PROCEDURES; HUMAN; LABORATORY DIAGNOSIS; LINE PROBE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BEACON ASSAY; MOLECULAR DIAGNOSIS; MOLECULAR DRUG SUSCEPTIBILITY TESTING; MOLECULAR PROBE; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS COMPLEX; NEXT GENERATION SEQUENCING; NUCLEIC ACID AMPLIFICATION; PREDICTION; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; CLASSIFICATION; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR TYPING; PROCEDURES;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TYPING; MYCOBACTERIUM; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 84901199334     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2014.02.005     Document Type: Review

References (74)

1. CDC Reported tuberculosis in the United States, 2012 2013, Center for the Diseases Control and Prevention, Atlanta (GA).
2. Hoffner S. Unexpected high levels of multidrug-resistant tuberculosis present new challenges for tuberculosis control. Lancet 2012, 380(9851):1367-1369.
3. WHO. Global tuberculosis report. 2013. Geneva (Switzerland): World Health Organization. Available at:. WHO/HTM/TB/2013.11. http://wh1libdoc.who.int/publications/2013/9789241564656_eng.pdf.
4. WHO Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report in surveillance and response 2011, World Health Organization, Geneva (Switzerland), March, 6, 2011.
5. WHO Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement 2008, World Health Organization, Geneva (Switzerland).
6. WHO Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB 2010, World Health Organization, Geneva (Switzerland).
7. WHO. Policy statement: Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampin resistance: Xpert MTB/RIF system. Geneva (Switzerland): World Health Organization. Available at:. WHO/HTM/TB/2011.4. 2011. http://whlibdoc.who.int/publications/2011/9789241501545.
8. Boehme C.C., Nabeta P., Hillemann D., et al. Rapid molecular detection of tuberculosis and rifampin resistance. NEngl J Med 2010, 363(11):1005-1015.
9. Drobniewski F., Nikolayevskyy V., Maxeiner H., et al. Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation. BMC Med 2013, 11:190.
10. Banerjee R., Allen J., Lin S.Y., et al. Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California. JClin Microbiol 2010, 48(10):3779-3781.
11. CDC Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009, 58(1):7-10.
12. Marks S.M., Cronin W., Venkatappa T., et al. The health-system benefits and cost-effectiveness of using Mycobacterium tuberculosis direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States. Clin Infect Dis 2013, 57(4):532-542.
13. Boehme C.C., Nicol M.P., Nabeta P., et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011, 377(9776):1495-1505.
14. Meyer-Rath G., Schnippel K., Long L., et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 2012, 7(5):e36966.
15. de Lange C. Diagnosis: waiting for results. Nature 2013, 502(7470):S10-S12.
16. WHO Global tuberculosis report 2012 2012, World Health Organization, Geneva (Switzerland).
17. Cole S., Brosch R., Parkhill J., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537-544.
18. Pfyffer G.E., Palicova F. Mycobacterium: general characteristics, laboratory detection and staining procedures. Manual of clinical microbiology 2011, 472-502. ASM Press, Washington, DC. 10th edition. J. Versalovic, K. Carroll, G. Funke (Eds.).
19. Hopewell P. Overview of clinical tuberculosis. Tuberculosis, pathogenesis, protection and control 1994, 25-46. ASM Press, Washington, DC. B. Bloom (Ed.).
20. Dannenberg A.J., Rook G. Pathogenesis of pulmonary tuberculosis: an interplay of tissue-damaging and macrophage-activating immune responses-dual mechanisms that control bacillary multiplication. Tuberculosis 1994, 459-481. ASM Press, Washington, DC. B. Bloom (Ed.).
21. Burman W. The value of invitro drug activity and pharmacokinetics in predicting the effectiveness of antimicrobial therapy: a critical review. Am J Med Sci 1997, 313(6):355-363.
22. Zhang Y., Heym B., Allen B., et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992, 358:591-593.
23. Lin S.Y., Rodwell T.C., Victor T., et al. Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. JClin Microbiol 2014, 52:475-482.
24. Alonso M., Palacios J.J., Herranz M., et al. Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category. JClin Microbiol 2011, 49(7):2688-2690.
25. Rigouts L., Gumusboga M., de Rijk W.B., et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. JClin Microbiol 2013, 51(8):2641-2645.
26. van Deun A., Barrera L., Bastian I., et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. JClin Microbiol 2009, 47(11):3501-3506.
27. Hazbon M.H., Brimacombe M., Bobadilla del Valle M., et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006, 50(8):2640-2649.
28. Wilson T.M., Collins D.M. ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol 1996, 19:1025-1034.
29. Campbell P.J., Morlock G.P., Sikes R.D., et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011, 55(5):2032-2041.
30. Engström A., Morcillo N., Imperiale B., et al. Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. JClin Microbiol 2012, 50(6):2026-2033.
31. García-Sierra N., Lacoma A., Prat C., et al. Pyrosequencing for rapid molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical specimens. JClin Microbiol 2011, 49(10):3683-3686.
32. Huang W.-L., Chen H.-Y., Kuo Y.-M., et al. Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. JClin Microbiol 2009, 47(8):2520-2524.
33. Mokrousov I., Otten T., Filipenko M., et al. Detection of isoniazid-resistant Mycobacterium tuberculosis strains by a multiplex allele-specific PCR assay targeting katG Codon 315 variation. JClin Microbiol 2002, 40(7):2509-2512.
34. Lee H., Cho S.N., Bang H.E., et al. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea. Int J Tuberc Lung Dis 2000, 4(5):441-447.
35. Lee A.S., Teo A.S., Wong S.-Y. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2001, 45(7):2157-2159.
36. Williams D.L., Spring L., Collins L., et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998, 42(7):1853-1857.
37. Ohno H., Koga H., Kohno S., et al. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother 1996, 40(4):1053-1056.
38. Tan Y., Hu Z., Zhao Y., et al. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. JClin Microbiol 2012, 50(1):81-85.
39. van Deun A., Aung K.J., Bola V., et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. JClin Microbiol 2013, 51(8):2633-2640.
40. Williamson D.A., Roberts S.A., Bower J.E., et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2012, 16(2):216-220.
41. Plinke C., Rusch-Gerdes S., Niemann S. Significance of mutations in embB Codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2006, 50(5):1900-1902.
42. Ahmad S., Jaber A.A., Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis 2007, 87(2):123-129.
43. Morlock G.P., Crawford J.T., Butler W.R., et al. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000, 44(9):2291-2295.
44. Kim H.J., Kwak H.K., Lee J., et al. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea. Int J Tuberc Lung Dis 2012, 16(1):98-103.
45. Piersimoni C., Mustazzolu A., Giannoni F., et al. Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum. JClin Microbiol 2013, 51(1):291-294.
46. Chedore P., Bertucci L., Wolfe J., et al. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. JClin Microbiol 2010, 48(1):300-301.
47. Werngren J., Sturegard E., Jureen P., et al. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. Antimicrob Agents Chemother 2012, 56(3):1253-1257.
48. Simons S.O., van Ingen J., van der Laan T., et al. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. JClin Microbiol 2012, 50(2):428-434.
49. Sirgel F.A., Warren R.M., Streicher E.M., et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. JAntimicrob Chemother 2012, 67(5):1088-1093.
50. Poissy J., Aubry A., Fernandez C., et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010, 54(11):4765-4771.
51. Huang W.-L., Chi T.-L., Wu M.-H., et al. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. JClin Microbiol 2011, 49(7):2502-2508.
52. Maruri F., Sterling T.R., Kaiga A.W., et al. Asystematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. JAntimicrob Chemother 2012, 67(4):819-831.
53. Maus C.E., Plikaytis B.B., Shinnick T.M. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49(8):3192-3197.
54. Brossier F., Veziris N., Aubry A., et al. Detection by GenoType MTBDRsl test ofcomplex mechanisms of resistance to second-line drugs and ethambutol inmultidrug-resistant Mycobacterium tuberculosis complex isolates. JClin Microbiol 2010, 48(5):1683-1689.
55. Georghiou S.B., Magana M., Garfein R.S., et al. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012, 7(3):e33275.
56. Piatek A.S., Tyagi S., Pol A.C., et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol 1998, 16(4):359-363.
57. Tyagi S., Kramer F.R. Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol 1996, 14:303-308.
58. Lawn S.D., Mwaba P., Bates M., et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013, 13(4):349-361.
59. Marlowe E.M., Novak-Weekley S.M., Cumpio J., et al. Evaluation of the cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. JClin Microbiol 2011, 49(4):1621-1623.
60. van Rie A., Mellet K., John M.A., et al. False-positive rifampicin resistance on Xpert(R) MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis 2012, 16(2):206-208.
61. CDC Availability of an assay for detecting Mycobacterium tuberculosis, including refiampin-resistant strains, and consideration for its use-United States, 2013. MMWR Morb Mortal Wkly Rep 2013, 62(41):821-827.
62. Ferro B.E., García P.K., Nieto L.M., et al. Predictive value of molecular drug resistance testing of Mycobacterium tuberculosis isolates in Valle del Cauca, Colombia. JClin Microbiol 2013, 51(7):2220-2224.
63. Said H.M., Kock M.M., Ismail N.A., et al. Evaluation of the GenoType(R) MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 2012, 16(1):104-109.
64. Bravo L.T., Tuohy M.J., Ang C., et al. Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. JClin Microbiol 2009, 47(12):3985-3990.
65. Garza-Gonzalez E., Gonzalez G.M., Renteria A., et al. Apyrosequencing method for molecular monitoring of regions in the inhA, ahpC and rpoB genes of Mycobacterium tuberculosis. Clin Microbiol Infect 2010, 16(6):607-612.
66. Guo Q., Zheng R.J., Zhu C.T., et al. Pyrosequencing for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a meta-analysis. Int J Tuberc Lung Dis 2013, 17(8):1008-1013. [review article].
67. Halse T.A., Edwards J., Cunningham P.L., et al. Combined real-time PCR and rpoB gene pyrosequencing for rapid identification of Mycobacterium tuberculosis and determination of rifampin resistance directly in clinical specimens. JClin Microbiol 2010, 48(4):1182-1188.
68. Jureen P., Engstrand L., Eriksson S., et al. Rapid detection of rifampin resistance in Mycobacterium tuberculosis by pyrosequencing technology. JClin Microbiol 2006, 44(6):1925-1929.
69. Marttila H.J., Makinen J., Marjamaki M., et al. Prospective evaluation of pyrosequencing for the rapid detection of isoniazid and rifampin resistance in clinical Mycobacterium tuberculosis isolates. Eur J Clin Microbiol Infect Dis 2009, 28:33-38.
70. Zhao J.-R., Bai Y.-J., Wang Y., et al. Development of a pyrosequencing approach for rapid screening of rifampin, isoniazid and ethambutol-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2005, 9:328-332.
71. Diggle M.A., Clarke S.C. Pyrosequencing (TM)-sequencing typing at the speed of light. Mol Biotechnol 2004, 28(2):129-138.
72. Daum L.T., Rodriguez J.D., Worthy S.A., et al. Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains. JClin Microbiol 2012, 50(12):3831-3837.
73. Quail M.A., Smith M., Coupland P., et al. Atale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 2012, 13:341.
74. Köser C.U., Bryant J.M., Becq J., et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. NEngl J Med 2013, 369(3):290-292.